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Yana Vinogradova,1 Carol Coupland,1 Julia Hippisley-Cox2
ABSTRACT
OBJECTIVE
To assess the risks of breast cancer associated with 
different types and durations of hormone replacement 
therapy (HRT).
DESIGN
Two nested case-control studies.
SETTING
UK general practices contributing to QResearch or 
Clinical Practice Research Datalink (CPRD), linked to 
hospital, mortality, social deprivation, and cancer 
registry (QResearch only) data.
PARTICIPANTS
98 611 women aged 50-79 with a primary diagnosis 
of breast cancer between 1998 and 2018, matched 
by age, general practice, and index date to 457 498 
female controls.
MAIN OUTCOME MEASURES
Breast cancer diagnosis from general practice, 
mortality, hospital, or cancer registry records. 
Odds ratios for HRT types, adjusted for personal 
characteristics, smoking status, alcohol consumption, 
comorbidities, family history, and other prescribed 
drugs. Separate results from QResearch or CPRD were 
combined.
RESULTS
Overall, 33 703 (34%) women with a diagnosis of 
breast cancer and 134 391 (31%) controls had used 
HRT prior to one year before the index date. Compared 
with never use, in recent users (<5 years) with long 
term use (≥5 years), oestrogen only therapy and 
combined oestrogen and progestogen therapy were 
both associated with increased risks of breast cancer 
(adjusted odds ratio 1.15 (95% confidence interval 
1.09 to 1.21) and 1.79 (1.73 to 1.85), respectively). 
For combined progestogens, the increased risk was 
highest for norethisterone (1.88, 1.79 to 1.99) and 
lowest for dydrogesterone (1.24, 1.03 to 1.48). Past 
long term use of oestrogen only therapy and past 
short term (<5 years) use of oestrogen-progestogen 
were not associated with increased risk. The risk 
associated with past long term oestrogen-progestogen 
use, however, remained increased (1.16, 1.11 to 
1.21). In recent oestrogen only users, between three 
(in younger women) and eight (in older women) extra 
cases per 10 000 women years would be expected, 
and in oestrogen-progestogen users between nine 
and 36 extra cases per 10 000 women years. For 
past oestrogen-progestogen users, the results would 
suggest between two and eight extra cases per 10 000 
women years.
CONCLUSION
This study has produced new generalisable estimates 
of the increased risks of breast cancer associated with 
use of different hormone replacement preparations 
in the UK. The levels of risks varied between types of 
HRT, with higher risks for combined treatments and for 
longer duration of use.
Introduction
Hormone replacement therapy (HRT) (also known 
as hormone therapy (HT) or menopausal hormonal 
therapy (MHT)) is prescribed to relieve the symptoms of 
menopause, which can be life changing. HRT is used by 
millions of women, sometimes over extended periods. 
A range of hormone combinations are available, 
each with different efficacy and side effects. HRT can 
bring several improvements to quality of life, and it 
can prevent osteoporosis. Concerns about adverse 
effects, particularly the increased risk of breast cancer 
associated with HRT,1 has, however, resulted in a 
substantial decrease in HRT use over the past 17 years.2 
Breast cancer is the most common cancer in women, 
with more than 55 000 women in the UK affected each 
year,3 so different drug use scenarios might result in 
substantial differences in the number of women who 
develop breast cancer, even though the risk differences 
between hormones might seem relatively small. 
Current clinical guidelines recommend use of HRT for 
no longer than five years and have signalled that more 
information is needed about the risks of breast cancer 
associated with different types of HRT.4 5
Randomised trials using enrolled participants 
are now impractical to investigate the risks of breast 
cancer associated with HRT because of the numbers 
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Long term systemic use of hormone replacement therapy (HRT) is associated 
with increased risks of breast cancer, mostly attributable to the progestogens 
medroxyprogesterone, norethisterone, and levonorgestrel
After discontinuation of treatment, the increased risks decline, but remain raised 
for some years
A recent large meta-analysis has reported higher than expected breast cancer 
risks associated with HRT
WHAT THIS STUDY ADDS
The study confirmed increased risks of breast cancer associated with long term 
use of oestrogen only therapy and combined oestrogen and progestogen therapy
The combined treatment associated with the lowest risk increase was estradiol-
dydrogesterone
The findings suggest lower increased risks of breast cancer associated with 
longer term HRT use, and a more noticeable decline in risks once treatment is 
stopped compared with the meta-analysis
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required and the length of follow-up. Trials would 
also be difficult to justify ethically, given the known 
harms that are associated with some types of HRT. 
Earlier trials have been limited, focusing on specific 
age groups possibly unrepresentative of women 
likely to request HRT or selecting specific types of 
HRT6 (the largest being the Women’s Health Initiative 
trial),7 or, because the design failed to distinguish 
between treatment types, looking only at overall 
effect or association.8-10 Observational studies are 
more feasible but require access to large datasets 
covering lengthy time periods; so far only the Million 
Women Study has approached the requisite power.10 
A recent meta-analysis published after our study 
commenced, pooled information from 24 prospective 
observational studies to provide more comprehensive 
data on the details of exposure and breast cancer risks 
for the most commonly prescribed oestrogens and 
progestogens.11 This meta-analysis reported that the 
risk of breast cancer is increased for both oestrogen 
only and oestrogen-progestogen current users, with, 
respectively, a 17% and 60% increase for 1-4 years of 
use and a 33% and 108% increase for 5-14 years of 
use. The results also showed a remaining increased 
risk even after discontinuation of HRT. As with 
many meta-analyses, however, the included studies 
were conducted in different settings, had different 
selection criteria, and had different definitions of 
exposure, so the data and original study designs 
were heterogeneous. The study provided information 
for the most commonly used HRT preparations, 
albeit with notably smaller statistical power for 
dydrogesterone—a progestogen previously found 
to be associated with a low increased risk of breast 
cancer.12 At publication, the focus of publicity was the 
higher than expected associations with breast cancer 
risks than had been suggested by earlier trials. The 
Medicine and Healthcare products Regulatory Agency 
subsequently raised an HRT drug safety alert specific 
to breast cancer, but this has since been questioned 
as having caused “considerable anxiety,” particularly 
for women who might need HRT for reasons other than 
menopausal symptoms.13
Our study focused on exposure to all the commonly 
prescribed types of HRT in the UK over the past 20 
years in a representative primary care population. 
We assessed the differences in risks associated with 
the individual component hormones used in HRT, 
including dydrogesterone. Our findings are based on 
prospectively collected electronic health records from 
the two largest UK primary care databases linked 
to secondary care data sources. We analysed these 
separately and then combined the results. In contrast 
with data and analytical designs used in studies 
included in the recent meta-analysis,11 our data were 
homogeneous, and the analytical approach was 
common. This has allowed us to gain a realistic picture 
of exposure in the UK to component hormones used in 
HRT, and the associations with increased breast cancer 
risk of specific treatments, providing consistently 
derived information for patients and doctors.
Methods
Study design
Full details for this study are available in the published 
protocol.14 To summarise, we undertook a nested case-
control study using the two largest UK primary care 
databases, QResearch and Clinical Practice Research 
Datalink (CPRD) GOLD, and utilised linked data from 
Hospital Episode Statistics (HES), Office for National 
Statistics (ONS) mortality data, and (QResearch only) 
cancer registry data. We included all general practices 
that had contributed data for at least three years 
and from these we identified two open cohorts of 
women aged between 50 and 79 and registered with 
the general practice between 1 January 1998 and 31 
December 2018. We excluded women with already 
diagnosed breast cancer or records of mastectomy at 
the cohort entry date, and, to ensure completeness, 
any with fewer than three years of medical records.
Selection of cases and controls
Across both databases, we identified all cases between 
1 January 1998 and 31 December 2018. From the 
QResearch database, we identified all cases of 
incident breast cancer using general practice, hospital 
admission, mortality, and cancer registry records. From 
CPRD, when practices were linked, we used general 
practice, hospital admission (up to 31 December 2017), 
and mortality data records (up to 13 February 2018) to 
identify cases, and, when not linked, general practice 
records only. Each case was matched to a maximum of 
five controls by year of birth and general practice using 
incidence density sampling.15 For each case in any data 
source, the date of the first breast cancer record became 
the index date for their matched controls. QResearch 
and CPRD GOLD use different computer systems to 
collect records from practices, and as patients can be 
registered with only one practice, there was no overlap 
of cases and controls.
Exposure to HRT
We extracted prescription information for all 
oestrogens, progestogens, and tibolone from practice 
records. Symptoms indicative of developing breast 
cancer before diagnosis could have resulted in 
cessation of HRT. To minimise this source of possible 
protopathic bias, we excluded prescriptions issued in 
the year before the index date.16
Exposure to HRT was taken as the date from when 
a woman received her first prescription containing 
systemic oestrogen (oral, subcutaneous, or 
transdermal) indicated to treat menopausal symptoms. 
If a woman received no prescription that contained a 
progestogen after this date, she was classified as an 
oestrogen only therapy user. If a woman received any 
prescription that contained a progestogen, she was 
classified as a combined therapy user. We also included 
topical oestrogen preparations (vaginal pessaries or 
cream) and tibolone, because both are commonly 
prescribed to menopausal women.
A large proportion of women switched between 
different combinations of oestrogens and progestogens, 
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so we analysed each hormonal preparation as a separate 
exposure. For oestrogen only users, we distinguished 
between types, doses, and application method, 
whereas for combined therapy users we analysed 
combinations of any oestrogen, concentrating on 
progestogen type and application method. If combined 
therapy users had also used oestrogen only therapy, 
we analysed the women as oestrogen-progestogen 
users but adjusted the combined exposure results to 
account for periods of oestrogen only treatment. For 
all treatments, the reference category was no exposure 
(never users) to HRT.
At the time of our study, two types of oestrogen 
(conjugated equine oestrogen and estradiol) 
and four types of progestogen (norethisterone 
acetate, levonorgestrel, medroxyprogesterone, and 
dydrogesterone) were commonly prescribed in the 
UK and were included in our analyses. Of these, 
sufficient data were available for estradiol, estradiol-
norethisterone, and oestrogen-levonorgestrel to 
facilitate separate analysis of application methods—
oral, transdermal, or injection, and (for levonorgestrel) 
intrauterine. We investigated two daily dosage levels 
of oestrogen: low (0.625 mg/day or less for oral 
conjugated equine oestrogen, 1 mg/day or less for oral 
estradiol, and 50 mg or less for transdermal estradiol) 
and high (all other dosage levels). Median dosages 
for each oestrogen and for each woman were also 
calculated and analysed.
We have not specified the type of oestrogen for 
combinations with progestogens, but in our data 
conjugated equine oestrogen was by far the most 
commonly prescribed drug in combination with 
medroxyprogesterone (only 16% of prescriptions 
included estradiol) and levonorgestrel (only 5% 
included estradiol). Estradiol was the only oestrogen 
prescribed in combination with norethisterone and 
dydrogesterone.
Our data showed that HRT prescriptions were 
frequently issued for three months, so we assessed 
the durations of use by summing the lengths of 
prescriptions in days, including gaps of fewer than 
90 days between prescriptions. Most (79%) repeated 
prescriptions were, however, issued within 30 days. 
We then categorised durations of use as never (0), 
less than 1 year, 1-2 years (≥1 and <3), 3-4 years 
(≥3 and <5), 5-9 years (≥5 and <10), and 10 years or 
more. Excluding prescriptions in the past year, the gap 
between the end of the last prescription and the index 
date was categorised as 1-2 years (>1 and <2), 2-4 years 
(≥2 and <4), 5-9 years (≥5 and <10), and 10 years or 
more.
Because some women discontinued HRT more than 
a year before the index date, and associated breast 
cancer risks might have diminished noticeably, we 
investigated two recency related exposures: recent, 
if the women had a prescription more than one year 
and less than five years before the index date (this 
includes current users of HRT at one year before the 
index date), and past, if their last prescription ended 
before that period (≥5 years before). Using these, we 
analysed different durations of exposures in relation to 
the recency of the last prescription.
Confounders
Analyses were all adjusted by the same factors—those 
that might have affected a doctor’s prescribing decision 
for HRT or might have affected a woman’s decision to 
take HRT or are associated with an increased breast 
cancer risk.3 11 14 The data for confounders were 
derived from practice or hospital records, and data for 
drugs were from practice records only. To minimise 
protopathic bias, records of confounders had to be 
from at least a year before the index date. Confounders 
included lifestyle factors (smoking status, alcohol 
consumption, body mass index (BMI), and Townsend 
fifth as a measure of deprivation (in QResearch only)), 
self-assigned ethnicity (based on practice and hospital 
data), family history of cancers and osteoporosis, 
history of other cancers, records of early and late 
menopause, oophorectomy or hysterectomy, uptake of 
mammography or scanning, menopausal symptoms, 
comorbidities, and use, or when possible, duration 
of use of other drugs. Comorbidities included benign 
breast disease, diabetes, and bipolar disorder or 
schizophrenia.14 Other drugs included combined and 
progestogen only contraceptive drugs, aspirin, non-
steroidal anti-inflammatory drugs, tamoxifen, and 
raloxifene. When numbers permitted, we categorised 
duration of use of other drugs up to one year before 
the index date as never, less than 1 year, 1-2 years, 
3-4 years, and 5 years or more. Early menopause was 
estimated from records of menopausal symptoms or 
of oophorectomy or hysterectomy before age 45 years. 
Late menopause was considered if the first menopause 
related record was after 55 years for women older than 
55 at the index date. For all other women we assumed 
onset of menopause was between age 50 and 55 years.
Statistical analysis
As data from QResearch and CPRD cannot be pooled, for 
all analyses we processed extracted datasets in parallel 
as similarly as possible. To calculate associations 
between breast cancer risk and different exposures 
to HRT, we used conditional logistic regression to 
estimate odds ratios with 95% confidence intervals. A 
small proportion of women had missing values for BMI, 
smoking status, and alcohol consumption, which we 
assumed to be missing at random. We imputed these 
separately for each dataset using chained equations 
over 10 imputed datasets, where the imputation model 
included all listed confounders, exposures, and case-
control status indicators, and we combined the odds 
ratios obtained from the imputed datasets using 
Rubin’s rule.17
We considered duration of exposure both in the form 
of defined categories of exposure and as a continuous 
variable. For ease of comparability with other studies 
and to simplify interpretation, our main results are 
presented using defined categories of exposure, 
with duration of HRT expressed in years. We used a 
meta-analytical technique to combine the obtained 
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odds ratios from the separate analyses run on each 
database.18 A fixed effect model with inverse variance 
weights was used for the main analysis and a random 
effect model as a sensitivity analysis. In the main 
tables and text we only include the combined results; 
the separate results for QResearch and CPRD are in the 
supplementary tables.
To model exposures as continuous variables, we ran 
separate analyses on each database using fractional 
polynomials to explore non-linear risk associations for 
durations of exposure, measured in days.19 This was 
done for both recent and past exposures to all the types 
of HRT under investigation. Variables found to have 
non-linear associations were then transformed into the 
suggested powers, the separate analyses were rerun, 
and the resulting coefficients and standard errors were 
combined.
Additional and sensitivity analyses
To assess possible age related differences in risks 
associated with exposures to hormone, we performed 
additional analyses for different age categories at the 
index date: 50-59 years, 60-69 years, and 70-79 years. 
We ran another subgroup analysis for women in three 
different BMI groups: less than 25, 25 up to 30, and 30 
or more. In this analysis, we included only controls in 
the same body mass category as their matched case.
For the main analysis, we considered women to 
have recently used HRT if they had a prescription 
between one and five years before the index date. The 
risk associated with HRT has been found to decrease 
rapidly after discontinuation,20 so we needed a 
measure showing excess of risk for the most recently 
exposed women. To assess this, we repeated the 
analysis, defining recent use as exposure between one 
and two years before the index date.
It is possible that some women were classified as 
never exposed only because they were not registered 
with the practice at the time when they had used 
HRT. Although any systematic difference between 
cases and controls is unlikely, we addressed this 
possible misclassification of exposure by repeating 
the analysis in a subgroup of women with at least 10 
years of medical records. Another sensitivity analysis 
dealt with unknown adherence to HRT, because it 
is possible that some women with apparent gaps 
between prescriptions had in fact spread their HRT 
supply over longer periods. In this analysis, we defined 
duration of HRT use as the period between the first 
HRT prescription and the last one prior to one year 
before the index date.
The main analysis was run on women aged 50 to 
79, which may include some premenopausal and 
perimenopausal women who have a higher risk of breast 
cancer.21 To deal with this and provide comparability 
of our results with those of a meta-analysis,11 we also 
ran an additional analysis restricting our sample to 
women aged 55 to 79.
To check our assumption of missing at random 
for some confounders, we compared patterns of 
missingness in exposed and non-exposed women 
and repeated the analyses, including only cases and 
controls with recorded values. In the final sensitivity 
analysis, we dealt with problems that might 
have arisen from the different levels of linkage in 
QResearch and CPRD. All QResearch practices were 
linked to deprivation, hospital, mortality, and cancer 
registry data, so cases could be identified using all 
sources of data. For CPRD, however, only 60% of 
practices were linked to deprivation, hospital, and 
mortality data, so to include data from all usable 
practices, we were limited to identifying cases from 
all available data. To assess the possible effect on our 
results, we ran an analysis using only fully linked 
CPRD practices.
To estimate the excess of breast cancer cases 
associated with different HRT exposures we calculated 
the incidence rate in the unexposed female population 
for different age categories (50-59, 60-69, and 70-79) 
using the underlying cohort from CPRD. The rate in the 
exposed population was derived by multiplying the 
baseline rate by relevant odds ratios obtained from the 
combined analysis.
We used Stata v16 for all analyses. A 1% level of 
statistical significance was used to allow for multiple 
comparisons. To facilitate comparison with other 
studies, however, we present the results as odds ratios 
with 95% confidence intervals.
Patient and public involvement
This epidemiological study investigated a research 
question recommended by a National Institute 
for Health and Care Excellence committee, which 
included lay members.5 It used routinely collected 
data and appropriate statistical techniques. The grant 
application process and the publication process of The 
BMJ both had lay involvement. No other lay people 
were involved in setting or extending the research 
question or the outcome measures in our study, nor 
were they involved in developing plans for the design 
or implementation of the study. However, to better 
understand motivations for starting HRT and possible 
adherence issues related to prescribed treatment, 
formal and informal conversations with some women 
taking HRT were also organised. In these, women 
generally reported high levels of adherence, regardless 
of whether they had sought treatment themselves 
or were recommended it by a doctor. Some of the 
women involved have also agreed to help further with 
interpretation and dissemination of the results through 
women’s menopausal forums.
Results
Overall, 59 999 cases of breast cancer were identified 
in QResearch between 1 January 1998 and 31 July 
2018, using general practice, hospital admissions, 
mortality, and cancer registry records. In total, 38 612 
breast cancer cases were identified in CPRD between 1 
January 1998 and 31 December 2018, using general 
practice records and, for linked practices, also using 
hospital admission records (until 31 December 2017) 
and mortality records (until 13 February 2018) (fig 1).
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Table 1 shows the characteristics of the cases and 
matched controls from QResearch and CPRD. Cases 
were more likely than controls to be overweight or 
obese (53% v 50%), to be former smokers (29% v 
27%), to have a record of benign breast disease (9% v 
6%) or other cancers (3.1% v 2.6%), or to have a family 
history of breast cancer (4% v 2.5%).
Exposure
Across both databases, 33 703 (34%) cases and 
142 391 (31%) controls had ever been exposed to 
HRT. Of those, 8860 (26%) cases and 42 799 (30%) 
controls had been exposed to oestrogen only therapy 
and 24 843 (74%) cases and 99 592 (70%) controls 
had been exposed to oestrogen-progestogen therapy 
(supplementary eTable 1). Women in the 60-69 age 
category were relatively more exposed to oestrogen 
only (47% in cases and controls) and oestrogen-
progestogen therapies (48% in cases and controls). 
A high proportion of women using oestrogen only 
therapy had undergone oophorectomy or hysterectomy 
(89% cases and 90% controls), but, overall, users of 
oestrogen only and oestrogen-progestogen therapies 
had characteristics broadly similar to those of never 
users for most confounders. Some women switched 
between hormones during HRT exposure. About 
20% of oestrogen only users had exposure to both 
oestrogens. About 57% of combined therapy users 
had only one oestrogen-progestogen combination 
recorded. About 0.6% of cases and controls started 
HRT in the year before the index date, but these are 
considered as never users in the analyses.
Overall exposure
Overall (or ever) exposure to HRT was associated 
with an increased risk of breast cancer (adjusted 
odds ratio 1.21, 95% confidence interval 1.19 to 
1.23). The increased risk was mostly attributable 
to oestrogen-progestogen therapy (1.26, 1.24 to 
1.29), with oestrogen only therapy showing a small 
increased risk (1.06, 1.03 to 1.10), both compared 
with never users (supplementary eTable 2). No 
increased risk was associated with oestrogen cream 
or vaginal preparations (supplementary eTable 
3). The risks associated with HRT increased with 
duration of use, but the associations were less strong 
for oestrogen only therapy and for tibolone than for 
oestrogen-progestogen therapy, apart from estradiol-
dydrogesterone preparations. Norethisterone, 
levonorgestrel, and medroxyprogesterone were 
associated with similar risks, increasing across all 
duration categories longer than one year. For all 
exposure durations, the combined treatment with 
the lowest associated risk increase was estradiol-
dydrogesterone. No differences were found between 
low and high doses of oestrogens or between different 
application methods for estradiol, norethisterone, or 
levonorgestrel (supplementary eTable 4).
Associations between use of HRT and risk of breast 
cancer rapidly decreased with increasing years of 
Excluded cases
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Fig 1 | Flow chart of included cases and controls
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Characteristics
QResearch CPRD
Cases Controls Cases Controls
Total 59 999 269 902 38 612 187 596
Mean (SD) age (years) 63.4 (8.3) 63.6 (8.3) 63.4 (8.3) 63.3 (8.3)
Age group (years):
 50-59 35.7 (21 448) 34.9 (94 327) 36.1 (13 946) 36.6 (68 597)
 60-69 37.4 (22 458) 37.6 (101 481) 37.7 (14 557) 37.6 (70 585)
 70-79 26.8 (16 093) 27.5 (74 094) 26.2 (10 109) 25.8 (48 414)
Mean (SD) years of records 10.5 (5.5) 10.4 (5.5) 15.4 (5.9) 16.3 (5.6)
Ethnicity:
 Recorded 69.3 (41 584) 70.4 (189 903) 71.3 (27 546) 65.0 (121 959)
 White or not recorded 96.1 (57 646) 95.1 (256 792) 97.9 (37 789) 97.7 (183 347)
 Bangladeshi 0.1 (73) 0.3 (691) 0.0 (9) 0.0 (85)
 Black African 0.3 (191) 0.5 (1450) 0.2 (60) 0.2 (298)
 Caribbean 0.7 (439) 0.9 (2299) 0.3 (119) 0.3 (588)
 Chinese 0.2 (115) 0.2 (654) 0.1 (48) 0.1 (223)
 Indian 1.0 (581) 1.1 (3078) 0.6 (226) 0.6 (1134)
 Other 0.7 (424) 0.8 (2216) 0.6 (222) 0.6 (1093)
 Other Asian 0.5 (281) 0.5 (1467) 0.2 (79) 0.3 (503)
 Pakistani 0.4 (249) 0.5 (1255) 0.2 (60) 0.2 (325)
Townsend fifth*: *) based on linked cases and controls
 1 (most affluent) 24.7 (14 810) 24.5 (66 100) 27.4 (6201) 27.1 (29 634)
 2 23.7 (14 191) 23.2 (62 617) 25.4 (5745) 25.1 (27 488)
 3 21.1 (12 630) 21.1 (56 830) 21.0 (4747) 20.9 (22 831)
 4 17.5 (10 492) 18.0 (48 495) 17.0 (3847) 17.2 (18 849)
 5 (most deprived) 13.1 (7876) 13.3 (35 860) 9.7 (2098) 9.8 (10 702)
Body mass index:
 Recorded 80.3 (48 190) 79.5 (214 580) 90.2 (34 834) 86.5 (162 297)
 Mean (SD) 27.5 (5.5) 27.2 (5.5) 27.9 (5.7) 27.6 (5.7)
 15-24 30.0 (17 999) 31.6 (85 193) 32.1 (12 405) 32.7 (61 395)
 25-29 27.8 (16 696) 27.0 (72 808) 31.3 (12 082) 30.2 (56 570)
 ≥30 22.5 (13 495) 21.0 (56 579) 26.8 (10 347) 23.6 (44 332)
Smoking status:
 Recorded 87.4 (52 411) 86.7 (233 955) 95.5 (36 890) 91.8 (172 123)
 Non-smoker 40.4 (24 241) 41.2 (111 282) 58.5 (22 585) 57.4 (107 617)
 Former smoker 32.7 (19 611) 31.6 (85 217) 22.2 (8589) 19.6 (36 761)
 Current smoker:
  Light (1-9 cigarettes/day) 7.6 (4549) 7.5 (20 259) 5.9 (2284) 6.1 (11 379)
  Moderate (10-19) 4.0 (2419) 4.0 (10 783) 5.5 (2141) 5.3 (9921)
  Heavy (≥20) 2.7 (1591) 2.4 (6414) 3.3 (1291) 3.4 (6445)
Alcohol consumption:
 Recorded 79.3 (47 566) 78.3 (211 354) 87.4 (33735) 83.8 (157 295)
 None 18.2 (10 949) 19.6 (52 896) 29.5 (11 376) 29.6 (55 519)
 Former use 8.7 (5198) 8.8 (23 638) 1.8 (712) 1.6 (2935)
 Current user:
  Trivial (<1unit/day) 30.9 (18 547) 30.9 (83 301) 31.9 (12 304) 31.0 (58 125)
  Light (1-2 units/day) 11.6 (6949) 10.8 (29 208) 16.7 (6434) 15.0 (28 090)
  Moderate (3-6) 9.4 (5610) 7.9 (21 215) 5.9 (2279) 5.4 (10 134)
  Heavy (7-9) 0.3 (206) 0.3 (718) 1.1 (416) 0.9 (1714)
  Very heavy (≥10) 0.2 (107) 0.1 (378) 0.6 (214) 0.4 (778)
History of other cancers:
 Any cancer 2.8 (1656) 2.4 (6570) 3.6 (1389) 3.0 (5540)
 Haematological 0.4 (252) 0.3 (936) 0.5 (180) 0.4 (755)
 Cervical 0.2 (114) 0.2 (612) 0.2 (73) 0.2 (440)
 Colorectal 0.5 (287) 0.4 (1202) 0.6 (234) 0.5 (976)
 Lung 0.1 (77) 0.1 (258) 0.1 (35) 0.1 (256)
 Melanoma 0.5 (305) 0.5 (1230) 0.5 (203) 0.4 (660)
 Ovarian 0.2 (103) 0.1 (375) 0.3 (110) 0.2 (436)
 Uterine 0.2 (101) 0.2 (434) 0.3 (130) 0.3 (481)
Chronic conditions:
 Benign breast disease 8.6 (5174) 5.5 (14 787) 9.3 (3591) 6.0 (11 186)
 Diabetes 6.9 (4112) 6.7 (17 972) 7.1 (2757) 6.6 (12 395)
 Mental health disorder 0.9 (542) 0.8 (2046) 0.9 (345) 0.8 (1521)
 Osteoporosis 3.3 (1985) 3.8 (10171) 4.0 (1558) 4.5 (8469)
Other characteristics:
 Early menopause 13.1 (7831) 14.0 (37 764) 11.0 (4230) 11.9 (22 365)
 Late menopause 3.2 (1948) 2.8 (7592) 8.0 (3093) 7.0 (13 225)
 Menopausal symptoms 13.2 (7930) 12.9 (34 803) 23.9 (9214) 22.7 (42 579)
Table 1 | Characteristics of women with breast cancer and matched controls one year before index date by database 
(QResearch and CPRD). Values are percentages (numbers) of participants unless stated otherwise
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discontinuation (supplementary eFigure 1 and eTable 
5). For oestrogen only, estradiol combined with 
norethisterone and dydrogesterone, and tibolone, no 
significantly increased risk was found from two years 
after discontinuation. For medroxyprogesterone, the 
risk was reduced after two years but remained raised 
until after five years; for levonorgestrel until after 10 
years.
Duration of recent and past exposures as 
categorical variables
Recent users of HRT (ie, those with prescriptions 
more than one year and less than five years before the 
index date) comprised 56% (18 879) of cases and 50% 
(70 931) of controls ever exposed to HRT. Figure 2 and 
figure 3 (supplementary eTable 6) show the associations 
between categorised durations of HRT and risks of 
breast cancer in women with recent and past exposures. 
The patterns of risks for recently exposed women were 
similar to those for overall exposures, but the risks were 
consistently higher and more pronounced, particularly 
for oestrogen-progestogen therapy. For women with 
past exposures, risks associated with longer durations 
of use of oestrogen-progestogen, particularly longer 
use of levonorgestrel (>3 years) and norethisterone (>5 
years), remained high, but for other hormones the risks 
were not statistically significant. Findings for recent 
exposures to different doses and applications also had 
similar patterns to the overall exposure analysis, but 
with higher odds ratios (supplementary eTable 7).
A further restriction to recency (defined now as one 
prescription or more in the period 1-2 years before the 
index date) resulted in fewer women in each category 
of exposure, but the increased risks associated 
with longer exposures were even more pronounced 
(supplementary eFigure 2). In HRT users, 40% (13 463) 
of cases and 32% (44 972) of controls ever exposed to 
HRT had one or more prescriptions in the period 1-2 
years before the index date. The patterns of risks for 
these recently exposed women were similar to those 
of overall exposures, but the risks were consistently 
higher and more pronounced for progestogens. For 
women with a last exposure more than two years before 
the index date, risks associated with long exposures to 
levonorgestrel (>3 years) remained high, but for other 
hormones the risks were not statistically significant 
(supplementary eFigure 3 and eTable 8).
Duration of recent and past exposures as 
continuous variables
Figure 4 (supplementary eTable 6) shows the 
associations between duration of different types of 
HRT and risks of breast cancer for recent (1-5 years 
before index date) and past users (prescriptions ≥5 
years previously). A linear relation was found between 
duration of exposure as a continuous variable for most 
types of HRT, with risk increasing uniformly over time. 
However, for recent exposure to oestrogen-progestogen 
or to estradiol-norethisterone, and for past exposure 
to oestrogen-medroxyprogesterone, square root 
transformations gave the best fit for an association 
with breast cancer risk, showing that risk for these 
treatments increased faster earlier in the exposure. 
Additions of further fractional polynomial terms were 
not statistically significant.
Risk increases for recent users were more pronounced 
than for past users, and different types of HRT showed 
different patterns of increase as the durations of 
exposure increased. Oestrogen-medroxyprogesterone 
and oestrogen-levonorgestrel formulations showed 
the greatest increases with duration. Oestrogen only 
(including separately conjugated equine oestrogen 
and estradiol), tibolone, and estradiol-dydrogesterone 
formulations showed the smallest increases with 
duration.
Subgroup analyses
The subgroup analyses for different age categories 
showed similar patterns in magnitudes of risk for recent 
and past exposures (fig 5, supplementary eFigure 4 
and eTables 9 and 10). The oldest age group (70-79) 
had a smaller number of recent (1-5 years before the 
Characteristics
QResearch CPRD
Cases Controls Cases Controls
 Mammography scans* 50.3 (30 170) 49.9 (134 728) 21.3 (8242) 20.1 (37 718)
 MRI/CT scans* 6.7 (4004) 6.6 (17 850) 2.6 (1004) 2.6 (4919)
 Oophorectomy or hysterectomy 20.7 (12 437) 21.6 (58 412) 21.4 (8264) 21.1 (39 583)
Family history:
 Any cancer 9.6 (5784) 7.9 (21 260) 5.0 (1939) 3.8 (7127)
 Breast cancer 4.3 (2598) 2.8 (7656) 3.4 (1329) 2.1 (3901)
 Cervical cancer 0.0 (22) 0.0 (112) 0.0 (19) 0.0 (51)
 Osteoporosis 0.9 (513) 0.8 (2147) 0.9 (355) 0.9 (1610)
 Ovarian cancer 0.2 (93) 0.1 (364) 0.2 (73) 0.2 (286)
 Uterine cancer 0.1 (45) 0.1 (172) 0.0 (7) 0.0 (29)
Any use of other drugs before index date:
 Aspirin 15.9 (9533) 16.3 (43 880) 16.3 (6276) 15.9 (29 869)
 Non-steroidal anti-inflammatory drugs 62.2 (37 305) 61.5 (166 024) 65.6 (25 329) 64.5 (120 920)
 Contraceptive drugs 10.9 (6554) 9.4 (25 494) 17.4 (6735) 17.7 (33 149)
 Tamoxifen 0.7 (436) 0.1 (277) 1.0 (389) 0.2 (394)
 Raloxifene 0.4 (224) 0.5 (1278) 0.4 (168) 0.5 (858)
MRI=magnetic resonance imaging; CT=computed tomography.
*Based on Hospital Episode Statistics and general practice data for QResearch and on general practice data for Clinical Practice Research Datalink (CPRD).
Table 1 | Continued
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index date) users and, although odds ratios appeared 
to be higher than for the younger age groups, the 
confidence intervals were too wide to reach statistical 
significance for oestrogen only users. The younger age 
group (50-59) had the lowest odds ratios, which could 
reflect shorter durations of exposure, particularly in 
the category of five years or more (supplementary 
eTables 9 and 10). The mean duration for the category 
of 1-4 years, however, was only slightly lower for the 
younger group but similar between the older groups.
Figure 6 presents the associations with breast cancer 
risk for recent and past exposures in different BMI 
categories (supplementary eFigure5 and eTables 11 
and 12). Overall, the pattern of risks in the subgroups 
were similar to those of the main analyses. For women 
with a higher BMI (>30), however, the risks associated 
with HRT for recent users appeared slightly lower 
than in women with a lower BMI, both for oestrogen 
only and for oestrogen-progestogen therapies. For 
oestrogen only therapy and more than five years of 
use, the association with risk of breast cancer was 
statistically significant only in the lowest BMI group 
(1.24, 1.11 to 1.35) compared with never use. For 
oestrogen-progestogen, more than five years of use was 
associated with the highest adjusted odds ratio in the 
lowest BMI group and the lowest adjusted odds ratio in 
the highest BMI group (1.93, 1.80 to 2.05 for BMI <25; 
1.71, 1.58 to 1.85 for BMI 25-30; and 1.38, 1.23 to 
1.55 for BMI >30). For past use, no difference between 
BMI groups was observed.
Excess numbers in HRT users
The crude incidence rate of breast cancer in the 
underlying CPRD cohort was 33.0 (95% confidence 
interval 32.7 to 33.3) per 10 000 women years, whereas 
the crude incidence rate in women not exposed to HRT 
was 31.5 (31.1 to 31.7) per 10 000 women years. The 
rate for unexposed women varied with age, with the 
lowest rate in younger women (28.2, 27.6 to 28.7 in 
women aged 50-59; 34.1, 33.4 to 34.8 in women 
aged 60-69; and 33.3, 32.6 to 34.0 in women aged 
70-79). The highest rate in the 60-69 years group was 
consistent with national data from cancer registration 
statistics in England.22
Table 2 and fig 7 contain incidence rates and excess 
rates of breast cancer in users of HRT at different ages 
and for different durations. The number of extra cases 
is consistently larger for older women for all exposures. 
Compared with never users, the estimated number of 
excess cases per 10 000 women years in recent long 
term (≥5 years) users of oestrogen only treatment was 
three in women aged 50-59, four in women aged 60 to 
69, and eight in women aged 70-79. Compared with 
never users, the number of excess cases per 10 000 
women years in recent long term users of oestrogen-
progestogen treatment was 15 in women aged 50-59, 
26 in women aged 60-69, and 36 in women aged 70-
79. For tibolone in recent long term users, the numbers 
exposed in younger women were too small to provide 
sufficient data, but within the older groups there are 
an estimated nine extra cases per 10 000 women years 
in women aged 60 to 69 and 15 extra cases per 10 000 
women years in women aged 70 to 79.
Sensitivity analyses
The sensitivity analysis run on women with at least 10 
years of recorded data showed similar patterns of risks 
associated with different durations of HRT use, but the 
Oestrogen only
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  <1 year
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1.09 (1.00 to 1.19)
1.08 (1.00 to 1.16)
1.15 (1.07 to 1.24)
1.14 (1.08 to 1.21)
1.17 (1.08 to 1.27)
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Fig 2 | Recent and past use of oestrogen, oestrogen-progestogen, and tibolone in association with breast cancer risk. Odds ratios are with reference 
to never users and adjusted for smoking status, alcohol consumption, Townsend fifth (QResearch only), body mass index, ethnicity, history of other 
cancers, oophorectomy or hysterectomy, records of early and late menopause, menopausal symptoms, mammography or scans, family history, 
comorbidities, other drugs, and years of data. Cases are matched to controls by age, general practice, and index date
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risks appeared slightly higher, particularly for exposure 
to oestrogen-progestogen combinations of between 
five and 10 years (supplementary eFigure 6 and eTable 
13). The sensitivity analysis on the subgroup of women 
aged 55 to 79 showed similar patterns of risks, with 
all values consistent with the subgroup analyses for 
different age groups (supplementary eFigure 6 and 
eTable 14). The sensitivity analysis with duration 
of exposure defined as from the first prescription of 
HRT to the end of the last prescription showed results 
similar to those of the main analysis (supplementary 
eTable 15). The results of analyses run on cases and 
controls without missing data for smoking status, 
alcohol consumption, and BMI were similar to those of 
the main analyses—as were the analysis restricted to 
CPRD cases and controls with linked data.
Discussion
This large observational study found that exposure to 
most HRT drugs is associated with an increased risk 
of breast cancer. In comparison with a recent meta-
analysis, however, our findings generally suggest lower 
increased risk associations between longer term HRT 
use and breast cancer, and we report a more noticeable 
decline in risks once HRT has stopped. Risk increases 
were mostly associated with oestrogen-progestogen 
treatments, but small increases were also associated 
with oestrogen only treatments. For all exposure 
durations, the combined treatment with the lowest 
associated risk increase was estradiol-dydrogesterone. 
Associations for all treatments depended on duration, 
with no increased risks for less than one year of 
treatment but increasing risks for longer exposures 
to medroxyprogesterone, norethisterone, and 
levonorgestrel. Associations were more pronounced 
for older women and less noticeable for obese women.
Strengths and weaknesses of this study
The main strengths of this original study are its size, 
consistent sources of primary care data, almost 
complete follow-up of diagnoses using linked data, 
consistent design, and resulting generalisability of the 
findings. Combining results from the two largest UK 
primary care research databases with national coverage 
has provided increased power, representiveness, and 
wide geographical coverage of included practices. The 
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Fig 3 | Recent and past use of different hormones in association with breast cancer risk. Odds ratios are with reference to never users and adjusted 
for smoking status, alcohol consumption, Townsend fifth (QResearch only), body mass index, ethnicity, history of other cancers, oophorectomy or 
hysterectomy, records of early and late menopause, menopausal symptoms, mammography or scans, family history, comorbidities, other drugs, and 
years of data. Cases are matched to controls by age, general practice, and index date
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study relates to an important health problem and used 
only objective information on prescriptions for HRT 
in the UK, facilitating inclusion of the full range of 
preparations available within this national setting and 
presenting in detail the increased risk of breast cancer 
associated with usage patterns. The follow-up and 
validation of breast cancer diagnoses through linkages 
to hospital, mortality, and cancer registry (QResearch 
only) data reduced both ascertainment and recording 
bias. As our study was based on routinely collected 
data, it was also not susceptible to recall bias. Matching 
by general practice enabled consideration of possible 
differences in prescribing and recording patterns 
across practices. Differences in menopause onset and 
age at start of HRT were partially dealt with through 
matching by age. The results were also adjusted for 
information on lifestyle, comorbidities, and use of 
other drugs, and the study presents subgroup analyses 
for women in different age groups and in different 
BMI categories. Protopathic bias, from diagnostic and 
prescribing problems created by symptoms common 
to early breast cancer and onset of menopause, was 
minimised by excluding prescriptions issued in the 
year before the index date.
Some limitations of this study arise from inevitable 
shortfalls in completeness and accuracy within any 
routinely collected dataset. A small proportion of 
women had missing information on smoking status, 
alcohol consumption, and BMI, but these were dealt 
with by multiple imputation. As we did not have 
reliable data for age at onset of menopause for all 
women, we estimated onset from the first menopause 
specific record before the earliest HRT prescription. For 
women with no such record we assumed onset within 
the most common age range of 50 to 54 years. We did 
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Fig 4 | Adjusted odds ratios for different durations of recent and past exposures to hormone replacement therapies in association with breast cancer 
risk. Odds ratios are with reference to never users and adjusted for smoking status, alcohol consumption, Townsend fifth (QResearch only), body 
mass index, ethnicity, history of other cancers, oophorectomy or hysterectomy, records of early and late menopause, menopausal symptoms, 
mammography or scans, family history, comorbidities, other drugs, and years of data. Cases are matched to controls by age, general practice, and 
index date. Model includes fractional polynomial terms for recent use of oestrogen-progestogen (power 0.5), estradiol-norethisterone (power 0.5), 
past use of oestrogen-levonorgestrel (power 0.5), and linear terms (1) for all other exposures
 on 2 N
ovem










J: first published as 10.1136/bm
j.m






the bmj | BMJ 2020;371:m3873 | doi: 10.1136/bmj.m3873 11
and sequential HRT because these regimens are 
prescribed at different times after menopause. As our 
cases and controls were matched by age, they would 
likely have been prescribed similar regimens, making 
a comparison infeasible. Our primary focus, anyway, 
was recent long term exposure.
No reliable data were available for established risk 
factors for breast cancer, such as parity or time of 
the first pregnancy, but there is no evidence to show 
that these are related to HRT use. No data for physical 
activity were available, but a possible risk reduction for 
active women has been shown not to be influenced by 
menopausal status.23 Some women might have joined 
their current practice after the onset of menopause, 
so records of past treatments might not have been 
available. The results from the subgroup restricted to 
women with at least 10 years of data, however, showed 
a similar pattern of risk associations to that of the 
main analysis. Use of HRT might have the side effect of 
increased breast density, possibly masking cancers and 
leading to diagnostic delays,24 which could shift odds 
ratios for short duration towards unity. Also, although 
there was no information about adherence to HRT, 
any systematic differences between cases and controls 
seems unlikely because information was recorded 
prospectively before diagnosis. Conversations with lay 
women involved in this research also revealed a high 
adherence to HRT.
Strengths and weaknesses in relation to other studies
Our study used a nested case-control design, so it did 
not follow women prospectively from the start of HRT 
or assess average lifetime risks. Rather, it looked back 
at already recorded exposures to HRT for women with 
a diagnosis of breast cancer and matched controls in 
the age range 50 to 79 and produced comparisons 
of risks averaged across all time points at which 
diagnoses in the datasets occurred. The study is based 
on data derived from real world treatment settings, 
when women might not have had a constant supply 
of a preparation and might have needed to switch 
drugs during the study period. Including all exposures 
prescribed over time allowed us to present information 
for a wide range of common types of HRT.
Most trials produced results for a more restricted 
number of treatments. A meta-analysis of existing 
Recent use
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Fig 5 | Use of oestrogen only, oestrogen-progestogen, and tibolone in women of different ages in association with breast cancer risk. Odds ratios are 
with reference to never users and adjusted for smoking status, alcohol consumption, Townsend fifth (QResearch only), body mass index, ethnicity, 
history of other cancers, oophorectomy or hysterectomy, records of early and late menopause, menopausal symptoms, mammography or scans, 
family history, comorbidities, other drugs, and years of data. Cases are matched to controls by age, general practice, and index date
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trials,7 taken largely from the Women’s Health 
Initiative study, provided estimates only for the 
specific treatments of conjugated equine oestrogen 
with and without medroxyprogesterone.6 In contrast to 
our estimates of a slightly increased risk for long term 
users of conjugated equine oestrogen (average duration 
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Fig 6 | Use of oestrogen-only, oestrogen-progestogen, and tibolone in women of different body mass index in association with breast cancer 
risk. Odds ratios are with reference to never users and adjusted for smoking status, alcohol consumption, Townsend fifth (QResearch only), body 
mass index, ethnicity, history of other cancers, oophorectomy or hysterectomy, records of early and late menopause, menopausal symptoms, 
mammography or scans, family history, comorbidities, other drugs, and years of data. Cases are matched to controls by age, general practice, and 
index date
Table 2 | Incidence rates and excess of cases of breast cancer compared with never use per 10 000 women years by 
different age categories and different durations and recency of hormone replacement therapy (HRT) use
HRT and duration of use by recency
Age group (years)
50-59 60-69 70-79
Rate per 10 000 Extra cases Rate per 10 000 Extra cases Rate per 10 000 Extra cases
Never use 26 – 31 – 30 –
Oestrogen only:
 Recent use 1-5 years 29 3 35 4 38 8
 Recent use ≥5 years 28 – 36 5 38 8
Oestrogen-progestogen:
 Past use 1-5 years 25 – 33 2 35 5
 Past use ≥5 years 24 – 36 5 38 8
 Recent use 1-<5 years 35 9 46 15 49 19
 Recent use ≥5 years 41 15 57 26 66 36
Tibolone:
 Recent use 1-<5 years 28 – 35 4 38 8
 Recent use ≥5 years 31 – 40 9 45 15
Rates were estimated using rates in unexposed populations from Clinical Practice Research Datalink multiplied by adjusted odds ratios derived from 
subgroup analyses for different age categories (see fig 5). Extra cases were reported only for statistically significant findings. Recent use is within one and 
five years; past use is five years before the index date. 
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for recent exposure of 5.6 years, odds ratio 1.07, 95% 
confidence interval 1.01 to 1.12), the meta-analysis 
found no difference in risk of breast cancer (relative 
risk 0.79, 95% confidence interval 0.61 to 1.02) after a 
mean duration of 7.2 years. The observed relative risk 
for the combined conjugated equine oestrogen with 
medroxyprogesterone therapy after a mean duration 
of 5.6 years (1.27, 1.03 to 1.56) was similar to our 
findings for recent exposure, with an average duration 
of 3.7 years (odds ratio 1.35, 1.30 to 1.41).
Our estimates were consistent with previous 
observational studies.9 25-27 The Million Women 
Study28 29 showed slightly higher risks than our study: 
for recent oestrogen only users a relative risk of 1.30 
(95% confidence interval 1.21 to 1.40) compared with 
our odds ratio of 1.12 (1.08 to 1.16), and for recent 
oestrogen-progestogen users a relative risk of 2.00 
(1.88 to 2.12) compared with our odds ratio of 1.51 
(1.47 to 1.54). However, the Million Women Study 
only covered a selected population of women who 
had undergone mammography, and the initial study 
used just a single baseline questionnaire to collect 
information.28 Taken together, the relatively high 
proportion of HRT users in the initial study (55% were 
ever users and 35% were current users) and the less 
than 65% response rate at three years of follow-up, 
which would be expected also to be skewed towards 
HRT users, would suggest that women who used HRT 
were more likely to have participated.29
In general, some inconsistency was found between 
the proportions of women exposed to HRT in data 
used for our study and those used in the 2019 meta-
analysis.11 The predominant (40%) data source for 
the meta-analysis was from the Million Women Study, 
where, 51% of cases had ever been exposed to HRT 
and 18% of cases were current users (<5 years). The 
second largest data source, comprising 28% of the 
data used in the meta-analysis, was routinely collected 
CPRD data (one of the two data sources in our study), 
and here 40% of women with breast cancer had been 
exposed to HRT and 12% were current users. Both 
these exposure rates contrast with those in our study, 
which overall had 34% of cases ever exposed and 19% 
of cases with prescriptions within 1-5 years before 
diagnosis.
We cannot speculate on reasons for these differences 
in the CPRD data used because we do not have access 
to relevant information for the 2019 meta-analysis. 
That sample contained slightly older cases (mean age 
at diagnosis 66 v 63 in our sample) but no age range 
was reported. The estimations of risk for overall use 
of HRT in our CPRD analysis (odds ratio 1.21, 95% 
confidence interval 1.18, 1.25) were, however, similar 
to the CPRD specific estimations reported in the meta-
analysis (relative risk 1.25, 95% confidence interval 
1.20, 1.30). For recent use (prescriptions 1-2 years 
before the index date), when the proportions of HRT 
users in CPRD data used in our study and in the meta-
analysis were closest, the estimates of risk were also 
similar. In our analysis of CPRD data on recent use, the 
odds ratios were 1.25 (1.17 to 1.34) for oestrogen only 
and 1.91 (1.83 to 1.99) for oestrogen-progestogen, 
whereas for the CPRD data used in the meta-analysis 
the corresponding findings were 1.36 (1.25 to 1.4) and 
2.16 (2.02 to 2.31).
Comparative assessment of the findings from 
the 2019 meta-analysis is in general complicated 
by the heterogeneity of included studies and data 
sources. The meta-analysis included data from 24 
differently designed prospective studies from around 
the world. Differences between findings from our 
large, consistently designed study and those from the 
meta-analysis might be related to the different periods 
covered by included studies or several problems 
relating to the different data sources. Some studies 
used routinely collected data with different definitions 
of exposure,9 30 some used questionnaires with a single 
baseline assessment of exposure,27 28 31 and others 
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Fig 7 | Incident breast cancer rate per 10 000 women years for women unexposed 
and exposed for different durations to different hormone replacement therapies by 
age range. Rates were estimated using rates in unexposed populations multiplied 
by adjusted odds ratios derived from subgroup analyses for different age categories 
(see fig 5)
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used repeated biennial questionnaires.25 32 Some 
participants were recruited from different countries 
with ever exposure levels varying from 19% to 69%,8 
and some studies were from different profession 
related populations.8 25
Overall, our results were broadly in line with those 
of the meta-analysis11 but with slightly lower risks for 
long term exposures. This might partly be explained 
by almost half of the cases in the meta-analysis 
coming from the Million Women Study. For current 
use, however, the meta-analysis reported similar 
associations with risk of breast cancer, regardless 
of whether such use was restricted to HRT exposure 
within the past five years or within the past two 
years. By contrast, we found associations to be more 
pronounced for users with a prescription recency of 
1-2 years before the index date, with higher odds ratios 
than for an exposure recency of 1-5 years. Our results 
with a recency definition of 1-2 years were broadly 
similar to those of the meta-analysis for either of their 
definitions of current use, whereas our findings for 
1-5 years recency were lower. The difference in risk 
found by us seems to be more in line with previous 
expectations of declines in risk after cessation of HRT.7
Our findings for oestrogen only users with recent 
(1-5 years) use of more than five years (odds ratio 1.15, 
95% confidence interval 1.09 to 1.21) were lower 
than those from the meta-analysis (relative risk 1.33, 
95% confidence interval 1.28 to 1.38).11 Our study 
also found a marginally higher risk associated with 
estradiol than with conjugated equine oestrogen. For 
oestrogen-progestogen therapy, our finding for recent 
use of more than five years duration was also lower 
(1.79, 1.73 to 1.85) than the meta-analysis estimate 
(2.08, 2.02 to 2.15). Despite the similar average 
duration of exposures between our study and those in 
the meta-analysis, our findings for the different types 
of the most common progestogens and tibolone were 
consistently lower than those of the meta-analysis 
(supplementary eTable 16).
For dydrogesterone, our study found lower risks 
associated with more than five years of exposure than 
in the meta-analysis (1.24, 1.03 to 1.48 v 1.41, 1.17 
to 1.71).11 The risk from dydrogesterone was much 
lower than for any other progestogen, but one of our 
sensitivity analyses did show a statistically significant 
increased risk for a small subgroup of dydrogesterone 
users—those with a prescription 1-2 years before the 
index date and more than five years of use (112 cases, 
odds ratio 1.47, 1.19 to 1.83).
Our study showed differential risks associated with 
HRT use by age category. For recent exposures of more 
than five years’ duration, associated risks of breast 
cancer rose with increasing age category. This might 
partly be explained by generally longer usages in older 
age categories, although exposure of 1-4 years was 
similarly associated with increasing risk from younger 
to older age groups of women. Our findings for the 
70-79 age group for oestrogen only use (1.25, 1.11 to 
1.39) and for oestrogen-progestogen use (2.20, 2.02 to 
2.39) are in line with findings from the meta-analysis11 
for women who started HRT at the age of 55-59 and 
continued treatment for 5-14 years : oestrogen only 
use of 1.26 (1.12 to 1.41) and oestrogen-progestogen 
use of 1.97 (1.81 to 2.15).
The adiposity of included women differed between 
our study and previous studies. Mean BMI in our study 
(27.7 in cases) was higher than in other observational 
studies (average 25)33 but slightly lower than in the 
Women’s Health Initiative trial (28.5).34 This could help 
to explain overall differences in associations between 
our findings and those of other studies, although the 
mean BMI in our study reflects the distribution within 
women with breast cancer diagnosed in the general 
UK population over the study period. Our findings for 
women matched by age and category of BMI are detailed 
and comprehensive estimations of duration dependent 
associations for HRT exposure and breast cancer risk. 
They are broadly similar to those from previous studies 
and the 2019 meta-analysis,11 33 with the lowest 
associations between HRT use and risk of breast cancer 
in women in the highest BMI category. These concur 
with findings from the Million Women Study (which 
had relatively small numbers) and an earlier meta-
analysis.29 35 Some complex biological relation might 
exist between fat tissue and HRT,36 although it might 
also be related to differences in timeliness of diagnoses 
between women with different body weights.
Implications for clinicians and policymakers
This study delivers more generalisable estimates of 
the different risks of breast cancer associated with 
specific progestogen components of HRT, while 
confirming no increased risks from short term use 
of oestrogen only, estradiol-dydrogesterone, and 
tibolone. Increasing duration of use was generally 
associated with increased risk, with tibolone and 
estradiol-dydrogesterone showing the smallest risks. 
The frequency of prescribing for treatments including 
dydrogesterone was, however, much lower than for 
those including norethisterone, medroxyprogesterone, 
or levonorgestrel.
Unanswered questions and future research
In our study protocol we did not prespecify analyses 
relating to cancer stage or tumour type because these 
lay outside the main question of interest. Although 
information on risk related to individual progestogens 
could be improved, previous studies have shown that 
the associated risks between HRT and tumour types 
might differ, with higher risks of developing oestrogen 
receptor positive tumours and lobular tumours.11 
Knowing the cancer stage could also address the 
question of risk differences between women of various 
body weights, to clarify whether systematic differences 
might exist in diagnostic delay. Other unknowns 
include questions about breast cancer survival rates 
and all cause mortality in women using HRT.13
Conclusion
This large observational study of HRT and breast 
cancer risk based on two large primary care databases 
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analysed in an identical manner has confirmed the 
excess risk to be attributable mostly to combined 
treatments, with the lowest risks associated with use of 
the least commonly prescribed dydrogesterone. Rarely 
prescribed tibolone also showed low increased risks.
Our findings of generally lower increased risks for 
combined HRT treatments and of more pronounced 
declines in risk once HRT has stopped, provide some 
counterbalance to the higher than expected risks 
reported in a recently published meta-analysis.11 Our 
results add more evidence to the existing knowledge 
base and should help doctors and women to identify 
the most appropriate HRT formulation and treatment 
regimen, and provide more consistently derived 
information for women’s health experts, healthcare 
researchers, and treatment policy professionals.
We acknowledge the contribution of EMIS practices who contribute to 
the QResearch database and EMIS and the University of Nottingham 
for expertise in establishing, developing, and supporting the 
QResearch database and the Chancellor masters and schools of 
the University of Oxford for continuing to develop and support the 
QResearch database. The Hospital Episode Statistics data used in 
this analysis are re-used by permission from the NHS Digital who 
retain the copyright. We thank the Office for National Statistics 
(ONS) for providing the mortality data. ONS and NHS Digital bear no 
responsibility for the analysis or interpretation of the data. This project 
involves data derived from patient level information collected by the 
NHS, as part of the care and support of patients with cancer. The 
data are collated, maintained, and quality assured by the National 
Cancer Registration and Analysis Service, which is part of Public 
Health England (PHE). Access to the data was facilitated by the PHE 
Office for Data Release. QResearch acknowledges funding from the 
National Institute for Health Research funded Nottingham Biomedical 
Research Centre until 31 January 2019 and the CRUK Cancer Centre 
and Wellcome Trust from 1 October 2019. Lauren Taylor (Division of 
Primary Care University of Nottingham) contributed clinical advice, in 
particular on the pharmacology of treatments and decisions made in 
the prescribing process, at the stage of interpreting the results and we 
should like to acknowledge these inputs with gratitude.
Contributors: YV contributed to the study protocol, reviewed the 
literature, designed the study, organised the extraction of CPRD 
data, did the analysis on both datasets and wrote the draft of the 
manuscript. JHC initiated the study, undertook the original literature 
review, drafted the study protocol, organised the extraction of the 
QResearch data, advised on the design and clinical aspects of the 
study and interpretation of the results and drafting of the paper. CC 
contributed to the development of the idea and the study design and 
advised on the analysis and interpretation of the results. JHC and 
CC critically reviewed the paper. YV is the guarantor of the study. All 
authors have approved the submitted version. The corresponding 
author attests that all listed authors meet authorship criteria and that 
no others meeting the criteria have been omitted.
Funding: This work is partially funded by the National Institute for 
Health Research (NIHR) School for Primary Care Research (project 
reference 848619) and by Cancer Research UK (grant No C5255/
A18085) through the cancer research UK Oxford Centre. The views 
expressed are those of the authors and not necessarily those of the 
NIHR or the Department of Health and Social Care.
Competing interests: All authors have completed the ICMJE uniform 
disclosure form at www.icmje.org/coi_disclosure.pdf and declare 
support from the National Institute for Health Research School for 
Primary Care Research and by Cancer Research UK through the cancer 
research UK Oxford Centre; JHC is professor of clinical epidemiology 
at the University of Oxford and unpaid director of QResearch, a 
not-for-profit organisation which is a joint partnership between the 
University of Oxford and EMIS (commercial IT supplier for 60% of 
general practices in the UK). JHC was a paid director of ClinRisk until 
2019, which produces open and closed source software to ensure 
the reliable and updatable implementation of clinical risk algorithms 
within clinical computer systems to help improve patient care; no 
other relationships or activities that could appear to have influenced 
the submitted work.
Ethical approval: The protocol for QResearch has been published in 
ePrints and was reviewed in accordance with the requirements for the 
East Midlands Derby Research Ethic Committee (ref 03/4/021). The 
protocol for CPRD has been approved by the Independent Scientific 
Advisory Committee for MHRA Database Research (N 16_282).
Data sharing: To guarantee the confidentiality of personal and 
health information only the authors have had access to the data 
during the study in accordance with the relevant licence agreements. 
Access to the QResearch data are according to the information on 
the QResearch website (www.qresearch.org). CPRD linked data were 
provided under a licence that does not permit sharing.
The lead author affirms that the manuscript is an honest, accurate, 
and transparent account of the study being reported; that no 
important aspects of the study have been omitted and that any 
discrepancies from the study as planned have been explained.
Dissemination to participants and related patient and public 
communities: The results of the study will be sent to University of 
Nottingham press office, to related patients, and to the funders. A lay 
summary will be created and published at SPCR NIHR and QResearch 
website.
Provenance and peer review: Not commissioned; externally peer 
reviewed.
This is an Open Access article distributed in accordance with the 
terms of the Creative Commons Attribution (CC BY 4.0) license, which 
permits others to distribute, remix, adapt and build upon this work, 
for commercial use, provided the original work is properly cited. See: 
http://creativecommons.org/licenses/by/4.0/.
1  Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J. Long-
term hormone therapy for perimenopausal and postmenopausal 
women. Cochrane Database Syst Rev 2017;1:CD004143. 
doi:10.1002/14651858.CD004143.pub5 
2  Parkin DM. doi:10. Cancers attributable to exposure to hormones 
in the UK in 2010. Br J Cancer 2011;105(Suppl 2):S42-8. 
doi:10.1038/bjc.2011.483 
3  Cancer Research UK. Risk factors for Breast Cancer. 2015. https://
www.cancerresearchuk.org/health-professional/cancer-statistics/
statistics-by-cancer-type/breast-cancer/risk-factors.
4  National Collaborating Centre for Women’s and Children’s Health. 
Menopause. Full guideline. National Institute for Health and Care 
Excellence. 2015 (Version 1.5)
5  National Institute for Health and Care Excellence. Menopause: 
diagnosis and management. NICE guideline NG23. 2015.
6  Gartlehner G, Patel SV, Feltner C, et al. Hormone therapy for the 
primary prevention of chronic conditions in postmenopausal 
women: Evidence report and systematic review for the US preventive 
services task force. JAMA 2017;318:2234-49. doi:10.1001/
jama.2017.16952 
7  Chlebowski RT, Rohan TE, Manson JE, et al. Breast Cancer After Use 
of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data 
From 2 Women’s Health Initiative Randomized Clinical Trials. JAMA 
Oncol 2015;1:296-305. doi:10.1001/jamaoncol.2015.0494 
8  Bakken K, Fournier A, Lund E, et al. Menopausal hormone therapy 
and breast cancer risk: impact of different treatments. The 
European Prospective Investigation into Cancer and Nutrition. Int J 
Cancer 2011;128:144-56. doi:10.1002/ijc.25314 
9  Román M, Graff-Iversen S, Weiderpass E, et al. Postmenopausal 
Hormone Therapy and Breast Cancer Prognostic Characteristics: 
A Linkage between Nationwide Registries. Cancer Epidemiol 
Biomarkers Prev 2016;25:1464-73. doi:10.1158/1055-9965.EPI-
16-0240 
10  Lee S, Kolonel L, Wilkens L, Wan P, Henderson B, Pike M. 
Postmenopausal hormone therapy and breast cancer risk: the 
Multiethnic Cohort. Int J Cancer 2006;118:1285-91. doi:10.1002/
ijc.21481 
11  Collaborative Group on Hormonal Factors in Breast Cancer. Type 
and timing of menopausal hormone therapy and breast cancer risk: 
individual participant meta-analysis of the worldwide epidemiological 
evidence. Lancet 2019;394:1159-68. doi:10.1016/S0140-
6736(19)31709-X 
12  Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for 
breast cancer associated with different hormone replacement 
therapies: results from the E3N cohort study. Breast Cancer Res 
Treat 2008;107:103-11. doi:10.1007/s10549-007-9523-x 
13  Rymer J, Brian K, Regan L. HRT and breast cancer risk. 
BMJ 2019;367:l5928. doi:10.1136/bmj.l5928 
14  Vinogradova Y, Coupland C, Hippisley-Cox J. Protocol to assess 
risk of breast cancer associated with use of hormone replacement 
therapy in real world settings: two nested case-control studies in 
primary care. 2019. https://nottingham-repository.worktribe.com/
output/2309731.
 on 2 N
ovem










J: first published as 10.1136/bm
j.m






No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
15  Etminan M. Pharmacoepidemiology II: the nested case-control study—a 
novel approach in pharmacoepidemiologic research. Pharmacotherapy 
2004;24:1105-9. doi:10.1592/phco.24.13.1105.38083 
16  Delgado-Rodríguez M, Llorca J. Bias. J Epidemiol Community 
Health 2004;58:635-41. doi:10.1136/jech.2003.008466 
17  Royston P. Multiple imputation of missing values. Stata 
J 2004;4:227-41. doi:10.1177/1536867X0400400301
18  Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic 
introduction to fixed-effect and random-effects models for meta-
analysis. Res Synth Methods 2010;1:97-111. doi:10.1002/jrsm.12 
19  Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials 
to model continuous risk variables in epidemiology. Int J 
Epidemiol 1999;28:964-74. doi:10.1093/ije/28.5.964 
20  Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone 
therapy and health outcomes during the intervention and extended 
poststopping phases of the Women’s Health Initiative randomized 
trials. JAMA 2013;310:1353-68. doi:10.1001/jama.2013.278040 
21  Collaborative Group on Hormonal Factors in Breast Cancer. 
Menarche, menopause, and breast cancer risk: individual participant 
meta-analysis, including 118 964 women with breast cancer from 
117 epidemiological studies. Lancet Oncol 2012;13:1141-51. 
doi:10.1016/S1470-2045(12)70425-4 




23  Pizot C, Boniol M, Mullie P, et al. Physical activity, hormone 
replacement therapy and breast cancer risk: A meta-analysis of 
prospective studies. Eur J Cancer 2016;52:138-54. doi:10.1016/j.
ejca.2015.10.063 
24  Zahl P-H, Mæhlen J. Bias in Observational Studies of the Association 
between Menopausal Hormone Therapy and Breast Cancer. PLoS 
One 2015;10:e0124076. doi:10.1371/journal.pone.0124076 
25  Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens 
and progestins and the risk of breast cancer in postmenopausal 
women. N Engl J Med 1995;332:1589-93. doi:10.1056/
NEJM199506153322401 
26  Prentice RL, Chlebowski RT, Stefanick ML, et al. Estrogen plus progestin 
therapy and breast cancer in recently postmenopausal women. Am J 
Epidemiol 2008;167:1207-16. doi:10.1093/aje/kwn044 
27  Saxena T, Lee E, Henderson KD, et al. Menopausal hormone therapy 
and subsequent risk of specific invasive breast cancer subtypes 
in the California Teachers Study. Cancer Epidemiol Biomarkers 
Prev 2010;19:2366-78. doi:10.1158/1055-9965.EPI-10-0162 
28  Million Women Study Collaborators. Breast cancer and 
hormone-replacement therapy in the Million Women Study. 
Lancet 2003;362:419-27.
29  Beral V, Reeves G, Bull D, Green J, Million Women Study Collaborators. 
Breast cancer risk in relation to the interval between menopause and 
starting hormone therapy. J Natl Cancer Inst 2011;103:296-305. 
doi:10.1093/jnci/djq527 
30  Opatrny L, Dell’Aniello S, Assouline S, Suissa S. Hormone 
replacement therapy use and variations in the risk of breast cancer. 
BJOG 2008;115:169-75, discussion 175. doi:10.1111/j.1471-
0528.2007.01520.x 
31  Bakken K, Alsaker E, Eggen AE, Lund E. Hormone replacement 
therapy and incidence of hormone-dependent cancers in the 
Norwegian Women and Cancer study. Int J Cancer 2004;112:130-4. 
doi:10.1002/ijc.20389 
32  Fournier A, Berrino F, Riboli E, Avenel V, Clavel-Chapelon F. Breast 
cancer risk in relation to different types of hormone replacement 
therapy in the E3N-EPIC cohort. Int J Cancer 2005;114:448-54. 
doi:10.1002/ijc.20710 
33  Wang K, Li F, Chen L, Lai YM, Zhang X, Li HY. Change in risk of breast 
cancer after receiving hormone replacement therapy by considering 
effect-modifiers: a systematic review and dose-response meta-
analysis of prospective studies. Oncotarget 2017;8:81109-24. 
doi:10.18632/oncotarget.20154 
34  Rossouw JE, Anderson GL, Prentice RL, et al, Writing Group for 
the Women’s Health Initiative Investigators. Risks and benefits 
of estrogen plus progestin in healthy postmenopausal women: 
principal results From the Women’s Health Initiative randomized 
controlled trial. JAMA 2002;288:321-33. doi:10.1001/
jama.288.3.321 
35  Collaborative Group on Hormonal Factors in Breast Cancer. Breast 
cancer and hormone replacement therapy: collaborative reanalysis 
of data from 51 epidemiological studies of 52,705 women with 
breast cancer and 108,411 women without breast cancer. Lancet 
1997;350:1047-59. doi:10.1016/S0140-6736(97)08233-0 
36  Feigelson HS, Jonas CR, Teras LR, Thun MJ, Calle EE. Weight gain, body 
mass index, hormone replacement therapy, and postmenopausal 
breast cancer in a large prospective study. Cancer Epidemiol 
Biomarkers Prev 2004;13:220-4. doi:10.1158/1055-9965.EPI-03-
0301 
Supplementary information: Tables e1-e16 and 
figures e1-e7
 on 2 N
ovem










J: first published as 10.1136/bm
j.m
3873 on 28 O
ctober 2020. D
ow
nloaded from
 
